Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

9567	Companies
189140	Keywords
120841	Articles
100922	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 05/12/2025 at 07:00, 7 months 10 days ago

Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals announces approval for pivotal Phase III ENIGMA-TRS program evaluating evenamide as add-on therapy in treatment-resistant schizophrenia patients. Study results expected in Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRIEF

published on 04/01/2025 at 07:05, 8 months 21 days ago

Newron Pharmaceuticals publie ses résultats financiers pour 2024 et présente un aperçu de 2025.

Résultats Financiers Développement D'Evenamide Traitement De La Schizophrénie Accords De Licence Perspectives 2025
BRIEF

published on 04/01/2025 at 07:05, 8 months 21 days ago

Newron Pharmaceuticals Reports 2024 Financial Results, Previews 2025

Financial Results Evenamide Development Schizophrenia Treatment Licensing Agreements Outlook 2025
PRESS RELEASE

published on 04/01/2025 at 07:00, 8 months 21 days ago

Newron presents 2024 financial results and provides 2025 outlook
Newron Pharmaceuticals presents 2024 financial results and 2025 outlook, focusing on evenamide development for schizophrenia treatment and strategic licensing agreements

Financial Results Newron Pharmaceuticals Evenamide Licensing Agreements 2025 Outlook
BRIEF

published on 03/24/2025 at 17:50, 8 months 29 days ago

Newron Pharmaceuticals nomme le Dr Chris Martin au poste de président indépendant

Conseil D'administration Newron Pharmaceuticals Chris Martin Leadership Biopharmaceutique Thérapie De La Schizophrénie
BRIEF

published on 03/24/2025 at 17:50, 8 months 29 days ago

Newron Pharmaceuticals Nominates Dr. Chris Martin as Independent Chairman

Board Of Directors Newron Pharmaceuticals Chris Martin Biopharma Leadership Schizophrenia Therapy
PRESS RELEASE

published on 03/24/2025 at 17:45, 8 months 29 days ago

Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
Newron Pharmaceuticals S.p.A. proposes Chris Martin, ex-CEO of ADC Therapeutics, as Independent Chairman succeeding Dr. Köstlin after 12 years. Martin an experienced biopharma leader

Chairman Biopharma Newron Pharmaceuticals Chris Martin ADC Therapeutics
BRIEF

published on 01/09/2025 at 07:05, 11 months 13 days ago

Accord de licence entre Newron et Myung In Pharm pour l'Evenamide en Corée du Sud

Evenamide Traitement De La Schizophrénie Contrat De Licence Essai De Phase III Thérapies Du Système Nerveux Central
BRIEF

published on 01/09/2025 at 07:05, 11 months 13 days ago

Newron and Myung In Pharm License Agreement for Evenamide in South Korea

Phase III Trial CNS Therapies Evenamide Schizophrenia Treatment License Agreement
PRESS RELEASE

published on 01/09/2025 at 07:00, 11 months 13 days ago

Newron and Myung In Pharm announce license agreement for evenamide in South Korea
Newron Pharmaceuticals S.p.A. and Myung In Pharm enter license agreement for evenamide in South Korea, aiming to develop innovative treatment option for schizophrenia patients

Newron Pharmaceuticals Evenamide License Agreement South Korea Myung In Pharm

Accesswire

Published on 12/22/2025 at 15:00, 4 hours 53 minutes ago

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Published on 12/22/2025 at 14:40, 5 hours 13 minutes ago

Namibia Critical Metals Inc. Receives Proceeds of $1,154,762 from Exercise of Warrants
Published on 12/22/2025 at 14:30, 5 hours 23 minutes ago

Prospect Ridge Updates Diamond Drill Program at 100% Owned Camelot Copper-Gold Project in B.C.'S Cariboo Mining District
Published on 12/22/2025 at 14:00, 5 hours 53 minutes ago

Rio Grande Resources Completes 2025 Field Program and Advances Drill Targeting at the Winston Gold-Silver Project
Published on 12/22/2025 at 14:00, 5 hours 53 minutes ago

PPX Mining Appoints Ernest Mast as President and CEO and Announces Stock Option Grants

View all ACCESSWIRE

EQS Group

Published on 12/22/2025 at 19:31, 22 minutes ago

EQS-Adhoc: Marley Spoon Group SE: CEO Daniel Raab Re-appointed and Contract to be Extended until June 2029
Published on 12/22/2025 at 19:00, 53 minutes ago

PATRIMOINE ET COMMERCE: Déclarations des transactions sur actions propres (hors contrat de liquidité) réalisées le 19 décembre 2025
Published on 12/22/2025 at 18:51, 1 hour 1 minute ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 12/22/2025 at 18:20, 1 hour 32 minutes ago

CGTN: How China drives high-quality development through technological innovation
Published on 12/22/2025 at 18:14, 1 hour 38 minutes ago

Alzchem Group AG paves the way for continuity and further growth: Management Board contracts of Andreas Niedermaier and Andreas Lösler extended ahead of schedule

Les Echos

Published on 12/22/2025 at 18:33, 1 hour 20 minutes ago

ABEO SE RENFORCE ET OBTIENT UNE TRÈS LARGE MAJORITÉ DU CAPITAL DE VOGO AVEC 90,84% DÉTENUS À L’ISSUE DE L’OFFRE RÉOUVERTE
Published on 12/22/2025 at 18:05, 1 hour 48 minutes ago

Covivio - Treasury shares transactions between December 15th , 2025 and December 19th, 2025
Published on 12/22/2025 at 18:05, 1 hour 48 minutes ago

Covivio - Déclaration des transactions sur actions propres réalisées du 15 décembre au 19 décembre 2025
Published on 12/22/2025 at 17:45, 2 hours 8 minutes ago

Déclaration des transactions sur actions propres réalisées du 15 au 19 décembre 2025 dans le cadre du programme de rachat d’actions
Published on 12/22/2025 at 17:35, 2 hours 18 minutes ago

DECLARATION HEBDOMADAIRE D'OPERATIONS EFFECTUEES DU 15 AU 19 DECEMBRE 2025

View all LES ECHOS COMFI WIRE